Barrionuevo-Sánchez María Isabel, Ariza-Solé Albert, Ortiz-Berbel Daniel, González-Costello José, Gómez-Hospital Joan Antoni, Lorente Victòria, Alegre Oriol, Llaó Isaac, Sánchez-Salado José Carlos, Gómez-Lara Josep, Blasco-Lucas Arnau, Comin-Colet Josep
Cardiology Department, Intensive Cardiac Care Unit, Bellvitge University Hospital, L' Hospitalet de Llobregat, Barcelona, Spain.
Cardiac Surgery Department, Heart Disease Institute, Bellvitge University Hospital, L' Hospitalet de Llobregat, Barcelona, Spain.
J Geriatr Cardiol. 2022 Feb 28;19(2):115-124. doi: 10.11909/j.issn.1671-5411.2022.02.003.
The Impella pump has emerged as a promising tool in patients with cardiogenic shock (CS). Despite its attractive properties, there are scarce data on the specific clinical setting and the potential role of Impella devices in CS patients from routine clinical practice.
This is an observational, retrospective, single center, cohort study. All consecutive patients with diagnosis of CS and undergoing support with Impella 2.5, Impella CP or Impella 5.0 from April 2015 to December 2020 were included. Baseline characteristics, management and outcomes were assessed according to CS severity, age and cause of CS. Main outcome measured was in-hospital mortality.
A total of 50 patients were included (median age: 59.3 ± 10 years). The most common cause of CS was acute coronary syndrome (ACS) (68%), followed by decompensation of previous cardiomyopathy (22%). A total of 13 patients (26%) had profound CS. Most patients (54%) improved pulmonary congestion at 48 h after Impella support. A total of 19 patients (38%) presented significant bleeding. In-hospital mortality was 42%. Among patients with profound CS ( = 13), five patients were previously supported with venoarterial extracorporeal membrane oxygenation. A total of eight patients (61.5%) died during the admission, and no patient achieved ventricular recovery. Older patients (≥ 67 years, = 10) had more comorbidities and the highest mortality (70%). Among patients with ACS ( = 34), 35.3% of patients had profound CS; and in most cases (52.9%), Impella support was performed as a bridge to recovery. In contrast, only one patient from the decompensated cardiomyopathy group ( = 11) presented with profound CS. In 90.9% of these cases, Impella support was used as a bridge to cardiac transplantation. There were no cases of death.
In this cohort of real-life CS patients, Impella devices were used in different settings, with different clinical profiles and management. Despite a significant rate of complications, mortality was acceptable and lower than those observed in other series.
Impella泵已成为治疗心源性休克(CS)患者的一种有前景的工具。尽管其具有吸引人的特性,但关于Impella装置在常规临床实践中CS患者的具体临床情况和潜在作用的数据却很少。
这是一项观察性、回顾性、单中心队列研究。纳入了2015年4月至2020年12月期间所有连续诊断为CS并接受Impella 2.5、Impella CP或Impella 5.0支持的患者。根据CS严重程度、年龄和CS病因评估基线特征、管理和结局。主要测量结局是住院死亡率。
共纳入50例患者(中位年龄:59.3±10岁)。CS最常见的病因是急性冠状动脉综合征(ACS)(68%),其次是既往心肌病失代偿(22%)。共有13例患者(26%)患有严重CS。大多数患者(54%)在Impella支持后48小时肺淤血得到改善。共有19例患者(38%)出现严重出血。住院死亡率为42%。在患有严重CS的患者(n = 13)中,有5例患者先前接受了静脉-动脉体外膜肺氧合支持。共有8例患者(61.5%)在住院期间死亡,没有患者实现心室恢复。老年患者(≥67岁,n = 10)有更多合并症且死亡率最高(70%)。在ACS患者(n = 34)中,35.3%的患者患有严重CS;在大多数情况下(52.9%),Impella支持作为恢复的桥梁进行。相比之下,失代偿性心肌病组(n = 11)中只有1例患者患有严重CS。在这些病例的90.9%中,Impella支持用作心脏移植的桥梁。没有死亡病例。
在这个真实生活中的CS患者队列中,Impella装置在不同的临床情况、具有不同临床特征和管理方式下使用。尽管并发症发生率较高,但死亡率是可以接受的,且低于其他系列观察到的死亡率。